"压实上市公司市值管理主体责任，推动优质上市公司积极开展股份回购，引导更多公司回购注销。"3 月15日，在国新办新闻发布会上，证监会副主席李超表示。 今年以来，上市公司回购热情高涨，回购计划数量猛增。据同花顺iFinD数据统计，截至3月16日，年内 已有821家A股公司发布830单回购计划（包括回购预案或股东提议），回购上限金额超900亿元。同 时，越来越多的上市公司加入到"注销式"回购的阵营，57家公司新增"注销式"回购计划，其中不乏千亿 元市值的行业龙头公司。 "'注销式'回购增多，反映了上市公司对自身股价的关注和维护，以及在当前市场环境下，上市公司对 于资本运营和市值管理的积极态度。这种操作方式有利于优化公司的资本结构，可以直接提高每股收 益，从而提振股价。"南开大学金融发展研究院院长田利辉对《证券日报》记者表示，同时，这也表明 公司对未来的盈利能力和发展前景充满信心，将助力提升股价和投资者信心。 "注销式"回购数量激增 据统计，除了上述57家新增"注销式"回购计划的公司，还有30家已披露回购计划的公司，将回购用途变 更为减资注销，两类公司合计达87家，已超过2023年全年的55家；披露的回购注销金额合 ...

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) increased by 0.02%, with notable stock performances including Jingtai Holdings (02228) up 7.38% and Fosun Pharma (02196) up 6.00% [3] - The Hong Kong Innovative Drug Selection ETF (520690) rose by 0.52%, reaching a latest price of 0.97 yuan, with a trading volume of 240.45 million yuan and a turnover rate of 0.62% [3] - Jingtai Holdings announced an expected comprehensive income of no less than 500 million yuan for the six months ending June 30, 2025, representing an increase of at least 387% compared to the same period in 2024 [3] Group 2 - The Hong Kong Innovative Drug Selection ETF reached a new high in scale at 385 million yuan and a new high in shares at 399 million [4] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 22.93 million yuan, totaling 42.28 million yuan [4] - The ETF's management fee is 0.50% and the custody fee is 0.10%, which are among the lowest in comparable funds [5] Group 3 - The HSSCPB index aims to reflect the performance of Hong Kong-listed companies involved in innovative drug research, development, and production [5] - The top ten weighted stocks in the HSSCPB index account for 78.05% of the total index weight, including companies like BeiGene (06160) and WuXi Biologics (02269) [5]

药明康德（603259）(02359)公布，2025年8月11日耗资约2799.56万元回购30.7万股A股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

智通财经APP讯，药明康德(02359)公布，2025年8月11日耗资约2799.56万元回购30.7万股A股股份。 ...

格隆汇8月11日丨药明康德(02359.HK)发布公告，2025年8月11日耗资2799.56万元人民币回购30.7万股A 股，回购价格每股90.61-92.33元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月8日 | 2,485,141,055 | | 0 | | 2,485,141,055 | | 1). 其他 (請註明) | | | % | | | | | 參見B部 | | | ...

张凌表示，欧洲已不再是Biotech等生物科技融资的热门区域，很多欧洲企业更倾向去美国融资，甚至 有不少大型药企如 阿斯利康等，考虑将上市地区，从伦敦转去美国。 不过他也提到一个值得关注的趋势，在过去一到两年，企业首选美国，目标进入美国资本市场，做 Crossover融资，甚至部分公司为了在美上市而转移注册地。 据瑞恩小编统计，今年(截至8月11日)香港新上市的55家中，14家来自医疗健康行业、占比25.5%。 来源：MoneyDJ 花旗集团投资银行医疗健康部亚太区主管 (Managing Director, Head of Asia Pacific Healthcare Investment Banking at Citigroup)张凌(Ling Zhang)周一(8月11日)在亚太生物科技投资论坛上表示，欧洲 生物科技融资热度下降，企业首选是去美国以及亚太市场，十二个月以前首选都是美国，但过去六个月 发生天翻地覆改变，出现东升西降趋势，不仅有中国资金的北水，国际资金也有积极参与。 但过去6个月出现东升西降趋势，香港资本市场突发猛进，美国生物科技资本市场反而相对安静。 他以指数举例，香港生物科技ETF今年 ...

Summary of WuXi XDC Cayman Inc. Conference Call Company and Industry Overview - **Company**: WuXi XDC Cayman Inc. - **Industry**: China Healthcare Key Points and Arguments 1. **MSCI Inclusion Impact**: Inclusion in the MSCI China All Share Index is expected to broaden the investor base, providing comfort to portfolio managers regarding stock tradeability and interest from generalist investors [5][1] 2. **Growth and Earnings Visibility**: WuXi XDC is noted for having the highest growth and earnings visibility within the WuXi family, with an expected earnings CAGR of over 30% from 2024 to 2028 [2][1] 3. **Competitive Position**: The company has a strong competitive moat and leading indicators, making it a top pick compared to its peers, WuXi Biologics and WuXi AppTec [2][1] 4. **Market Capitalization Growth**: From the beginning of 2025 to the end of July, WuXi XDC's market cap increased from US$4.7 billion to US$8.8 billion, representing an 87% growth, significantly outperforming the 35% growth of the healthcare sector [5][1] 5. **Financial Performance**: Preliminary results for the first half of 2025 exceeded expectations, and a doubling of formulation capacity is anticipated, indicating conservative guidance and a significant backlog addition [2][1] 6. **Valuation Metrics**: The company’s price target is set at HK$60.00, with a current price of HK$56.05, indicating a 7% upside potential. The market cap is approximately RMB 61.45 billion [3][1] 7. **Earnings Projections**: Projected EPS for the fiscal years ending in 2025, 2026, and 2027 are RMB 1.24, RMB 1.66, and RMB 2.17 respectively, with revenues expected to grow from RMB 4.05 billion in 2024 to RMB 9.66 billion in 2027 [3][1] 8. **Risks Identified**: Potential risks include a deceleration in biotech funding, missed sales expectations for late-stage projects, and lower-than-expected gross margin improvements from new facilities [8][1] Additional Important Information - **Analyst Ratings**: The stock is rated as "Overweight" with an attractive industry view, indicating a positive outlook for the company compared to its peers [3][1] - **Market Dynamics**: The inclusion in the MSCI index is expected to enhance liquidity, potentially shifting investment preferences towards WuXi XDC over its parent company [2][1] - **Long-term Growth Strategy**: The company is positioned for significant growth, supported by its development stage and market conditions, with a focus on expanding its capabilities and market presence [6][1]

Core Viewpoint - The investment value of innovative drugs is not a short-term pulse but a long-term industrial dividend, with optimal solutions for sharing this dividend through index tools in golden tracks [1] Group 1: Performance of Innovative Drug Indices - Since July, the National Index for Hong Kong Stock Connect Innovative Drugs and the China Securities Innovative Drug Industry Index have reached new highs, with year-to-date increases of 106.7% and 32.3% respectively as of July 31 [2] - The impressive performance of these indices reflects a decade-long transformation of China's innovative drug industry from "follower" to "leader" [2] - Recent inflows into ETFs tracking innovative drug indices have been significant, with a net inflow of 4.26 billion yuan from August 4 to August 8 and over 16 billion yuan since June [2] Group 2: Index Adjustments and Sensitivity - The recent upgrade of the Hong Kong Stock Innovative Drug Index aims to enhance its focus by excluding CXO companies and increasing adjustment frequency from semi-annual to quarterly, effective August 12 [3][4] - This adjustment allows the index to better capture the core drivers of the innovative drug industry, focusing on pharmaceutical companies that lead drug development and hold key patents [3] - The increased adjustment frequency enhances the index's sensitivity, enabling it to quickly identify emerging growth companies in a rapidly evolving market [4] Group 3: Policy Support for Innovative Drugs - The innovative drug industry has received significant policy support this year, with the State Council's 2025 strategic goal to create a globally competitive innovation ecosystem [5] - Multiple regulatory bodies have introduced supportive measures, including optimizing review processes and reopening IPO channels for unprofitable companies [6] - The 2024 medical insurance fund expenditure on innovative drugs is projected to be 3.9 times that of 2020, with an annual growth rate of 40% [7] Group 4: Market Dynamics and Future Outlook - By the end of 2024, China is expected to have 3,575 original innovative drugs in clinical trials, surpassing the U.S. and becoming the global leader [7] - The proportion of first-in-class (FIC) drugs has increased from less than 10% in 2015 to 24% in 2024, indicating a significant enhancement in original innovation capabilities [7] - The innovative drug market in China currently accounts for less than 10% of the total pharmaceutical market, indicating substantial growth potential compared to over 20% in other G20 countries [9] Group 5: Investment Opportunities in Innovative Drugs - The China Securities Innovative Drug Industry Index has shown a year-to-date increase of 32.3%, with significant upside potential remaining [8] - The long-term growth of the innovative drug market is supported by an aging population and increasing demand for treatments for chronic diseases and rare diseases [8] - Investing in ETFs that track the innovative drug sector provides a way to mitigate risks associated with individual stock investments while capitalizing on overall industry growth [9]